Kringle Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kringle Pharma, Inc.
Purdue will partner with Exicure to develop psoriasis therapies using the latter’s Spherical Nucleic Acid platform, while Sienna buys Creabilis to advance its psoriasis candidate to Phase III. Meanwhile, one focus of the Almirall/Nuevolution tie-up will be psoriatic arthritis.
Japan has been attempting to get its bioventure sector off the ground for as long as many in the industry can remember, certainly since I first started coming to the country more than 20 years ago. But progress continues to be glacially slow.
The Scrip Asia 100 analysis identifies 100 of the most influential players on the Asia-Pacific life sciences scene. Our shining stars are 10 of Asia's visionary leaders from the worlds of pharma business and science.
Kringle Pharma has set up its first overseas operation, a European subsidiary which will progress the clinical development of its lead recombinant hepatic growth factor therapy.
- Large Molecule
- Other Names / Subsidiaries
- Kringle Pharma Europe AB